tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
CASI Pharmaceuticals Faces Setback with FOLOTYN® License Expiration in China
PremiumCompany AnnouncementsCASI Pharmaceuticals Faces Setback with FOLOTYN® License Expiration in China
24d ago
CASI Pharmaceuticals Receives FDA Clearance for CID-103 IND Application
Premium
Company Announcements
CASI Pharmaceuticals Receives FDA Clearance for CID-103 IND Application
2M ago
Casi Pharmaceuticals announces FDA clearance of CID-103 IND application
Premium
The Fly
Casi Pharmaceuticals announces FDA clearance of CID-103 IND application
2M ago
CASI Pharmaceuticals: Strategic Divestments and Promising Clinical Developments Drive Buy Rating
PremiumRatingsCASI Pharmaceuticals: Strategic Divestments and Promising Clinical Developments Drive Buy Rating
4M ago
CASI Pharmaceuticals Reports Q1 2025 Results and Asset Divestiture in China
Premium
Company Announcements
CASI Pharmaceuticals Reports Q1 2025 Results and Asset Divestiture in China
4M ago
Casi Pharmaceuticals reports Q1 EPS (69c) vs. (71c) last year
Premium
The Fly
Casi Pharmaceuticals reports Q1 EPS (69c) vs. (71c) last year
4M ago
Casi Pharmaceuticals receives Nasdaq deficiency notice
PremiumThe FlyCasi Pharmaceuticals receives Nasdaq deficiency notice
5M ago
CASI Pharmaceuticals Moves to Arbitration in Dispute with Acrotech
Premium
Company Announcements
CASI Pharmaceuticals Moves to Arbitration in Dispute with Acrotech
5M ago
Casi Pharmaceuticals price target lowered to $4 from $6 at H.C. Wainwright
Premium
The Fly
Casi Pharmaceuticals price target lowered to $4 from $6 at H.C. Wainwright
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100